Cargando…

Multi-Omics Analysis Identified TMED2 as a Shared Potential Biomarker in Six Subtypes of Human Cancer

INTRODUCTION: Cancer is one of the most common malignancies and the leading cause of death worldwide. As a member of the transmembrane emp24 domain (Tmed)/p24 family of proteins, TMED2 expression variations have been documented earlier in only a few subtypes of human cancers, and the multi-omics pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Sial, Nuzhat, Saeed, Saba, Ahmad, Mukhtiar, Hameed, Yasir, Rehman, Abdul, Abbas, Mustansar, Asif, Rizwan, Ahmed, Hamad, Hussain, Muhammad Safdar, Rehman, Jalil Ur, Atif, Muhammad, Khan, Muhammad Rashid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544130/
https://www.ncbi.nlm.nih.gov/pubmed/34707394
http://dx.doi.org/10.2147/IJGM.S327367
_version_ 1784589756597796864
author Sial, Nuzhat
Saeed, Saba
Ahmad, Mukhtiar
Hameed, Yasir
Rehman, Abdul
Abbas, Mustansar
Asif, Rizwan
Ahmed, Hamad
Hussain, Muhammad Safdar
Rehman, Jalil Ur
Atif, Muhammad
Khan, Muhammad Rashid
author_facet Sial, Nuzhat
Saeed, Saba
Ahmad, Mukhtiar
Hameed, Yasir
Rehman, Abdul
Abbas, Mustansar
Asif, Rizwan
Ahmed, Hamad
Hussain, Muhammad Safdar
Rehman, Jalil Ur
Atif, Muhammad
Khan, Muhammad Rashid
author_sort Sial, Nuzhat
collection PubMed
description INTRODUCTION: Cancer is one of the most common malignancies and the leading cause of death worldwide. As a member of the transmembrane emp24 domain (Tmed)/p24 family of proteins, TMED2 expression variations have been documented earlier in only a few subtypes of human cancers, and the multi-omics profiling of TMED2 as a shared biomarker in different other subtypes of human cancers remains to be uncovered. METHODS: In the current study, TMED2 multi-omics analysis in 24 major subtypes of human cancer was performed using different authentic online databases and bioinformatics analysis including UALCAN, Kaplan–Meier (KM) plotter, Human Protein Atlas (HPA), GENT2, MEXPRESS, cBioportal, STRING, DAVID, TIMER, and CTD. RESULTS: In general, the TMED2 expression in 24 major subtypes of human cancers was higher relative to normal controls and was also strongly associated with the lower overall survival (OS) and relapse-free survival (RFS) duration of CESC, ESCA, HNSC, KIRC, LIHC, and LUAD patients. This implies that TMED2 plays a significant role in the development and progression of these cancers. Furthermore, the TMED2 overexpression was also correlated with different clinicopathological features of CESC, ESCA, HNSC, KIRC, LIHC, and LUAD patients. TMED2-associated genes network was involved in 3 diverse pathways, and finally, few stronger correlations were also explored between TMED2 expression and its promoter methylation level, genetic alterations, and CD8+ T immune cells level. CONCLUSION: In conclusion, via this in silico study, we have elucidated that TMED2 can serve as a shared diagnostic and prognostic biomarker in CESC, ESCA, HNSC, KIRC, LIHC, and LUAD patients of different clinicopathological features but, further in vitro and in vivo research should be carried out to confirm these findings.
format Online
Article
Text
id pubmed-8544130
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-85441302021-10-26 Multi-Omics Analysis Identified TMED2 as a Shared Potential Biomarker in Six Subtypes of Human Cancer Sial, Nuzhat Saeed, Saba Ahmad, Mukhtiar Hameed, Yasir Rehman, Abdul Abbas, Mustansar Asif, Rizwan Ahmed, Hamad Hussain, Muhammad Safdar Rehman, Jalil Ur Atif, Muhammad Khan, Muhammad Rashid Int J Gen Med Original Research INTRODUCTION: Cancer is one of the most common malignancies and the leading cause of death worldwide. As a member of the transmembrane emp24 domain (Tmed)/p24 family of proteins, TMED2 expression variations have been documented earlier in only a few subtypes of human cancers, and the multi-omics profiling of TMED2 as a shared biomarker in different other subtypes of human cancers remains to be uncovered. METHODS: In the current study, TMED2 multi-omics analysis in 24 major subtypes of human cancer was performed using different authentic online databases and bioinformatics analysis including UALCAN, Kaplan–Meier (KM) plotter, Human Protein Atlas (HPA), GENT2, MEXPRESS, cBioportal, STRING, DAVID, TIMER, and CTD. RESULTS: In general, the TMED2 expression in 24 major subtypes of human cancers was higher relative to normal controls and was also strongly associated with the lower overall survival (OS) and relapse-free survival (RFS) duration of CESC, ESCA, HNSC, KIRC, LIHC, and LUAD patients. This implies that TMED2 plays a significant role in the development and progression of these cancers. Furthermore, the TMED2 overexpression was also correlated with different clinicopathological features of CESC, ESCA, HNSC, KIRC, LIHC, and LUAD patients. TMED2-associated genes network was involved in 3 diverse pathways, and finally, few stronger correlations were also explored between TMED2 expression and its promoter methylation level, genetic alterations, and CD8+ T immune cells level. CONCLUSION: In conclusion, via this in silico study, we have elucidated that TMED2 can serve as a shared diagnostic and prognostic biomarker in CESC, ESCA, HNSC, KIRC, LIHC, and LUAD patients of different clinicopathological features but, further in vitro and in vivo research should be carried out to confirm these findings. Dove 2021-10-21 /pmc/articles/PMC8544130/ /pubmed/34707394 http://dx.doi.org/10.2147/IJGM.S327367 Text en © 2021 Sial et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Sial, Nuzhat
Saeed, Saba
Ahmad, Mukhtiar
Hameed, Yasir
Rehman, Abdul
Abbas, Mustansar
Asif, Rizwan
Ahmed, Hamad
Hussain, Muhammad Safdar
Rehman, Jalil Ur
Atif, Muhammad
Khan, Muhammad Rashid
Multi-Omics Analysis Identified TMED2 as a Shared Potential Biomarker in Six Subtypes of Human Cancer
title Multi-Omics Analysis Identified TMED2 as a Shared Potential Biomarker in Six Subtypes of Human Cancer
title_full Multi-Omics Analysis Identified TMED2 as a Shared Potential Biomarker in Six Subtypes of Human Cancer
title_fullStr Multi-Omics Analysis Identified TMED2 as a Shared Potential Biomarker in Six Subtypes of Human Cancer
title_full_unstemmed Multi-Omics Analysis Identified TMED2 as a Shared Potential Biomarker in Six Subtypes of Human Cancer
title_short Multi-Omics Analysis Identified TMED2 as a Shared Potential Biomarker in Six Subtypes of Human Cancer
title_sort multi-omics analysis identified tmed2 as a shared potential biomarker in six subtypes of human cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544130/
https://www.ncbi.nlm.nih.gov/pubmed/34707394
http://dx.doi.org/10.2147/IJGM.S327367
work_keys_str_mv AT sialnuzhat multiomicsanalysisidentifiedtmed2asasharedpotentialbiomarkerinsixsubtypesofhumancancer
AT saeedsaba multiomicsanalysisidentifiedtmed2asasharedpotentialbiomarkerinsixsubtypesofhumancancer
AT ahmadmukhtiar multiomicsanalysisidentifiedtmed2asasharedpotentialbiomarkerinsixsubtypesofhumancancer
AT hameedyasir multiomicsanalysisidentifiedtmed2asasharedpotentialbiomarkerinsixsubtypesofhumancancer
AT rehmanabdul multiomicsanalysisidentifiedtmed2asasharedpotentialbiomarkerinsixsubtypesofhumancancer
AT abbasmustansar multiomicsanalysisidentifiedtmed2asasharedpotentialbiomarkerinsixsubtypesofhumancancer
AT asifrizwan multiomicsanalysisidentifiedtmed2asasharedpotentialbiomarkerinsixsubtypesofhumancancer
AT ahmedhamad multiomicsanalysisidentifiedtmed2asasharedpotentialbiomarkerinsixsubtypesofhumancancer
AT hussainmuhammadsafdar multiomicsanalysisidentifiedtmed2asasharedpotentialbiomarkerinsixsubtypesofhumancancer
AT rehmanjalilur multiomicsanalysisidentifiedtmed2asasharedpotentialbiomarkerinsixsubtypesofhumancancer
AT atifmuhammad multiomicsanalysisidentifiedtmed2asasharedpotentialbiomarkerinsixsubtypesofhumancancer
AT khanmuhammadrashid multiomicsanalysisidentifiedtmed2asasharedpotentialbiomarkerinsixsubtypesofhumancancer